论文部分内容阅读
本文报告50例鼻咽癌病人、20例头颈部其他恶性肿瘤及21例正常人的血清总的免疫球蛋白(IgA)水平,各为363.36±287.09毫克%、320.41±104.65毫克%及233.75±110.80毫克%;唾液总的IgA水平,各为41.23±19.73毫克%、41.95±81.18毫克%及24.95±31.18毫克%。鼻咽癌病人无论在血清或唾液申的IgA水平都明显高于正常人,但与头颈部其他恶性肿瘤无显著差别。鼻咽癌病人的类疱疹病毒(EB),病毒核壳体抗原(VCA)—IgA抗体92%≥1:10,而头颈部其他恶性肿瘤及正常人阳性率在10%以下,VCA—IgG≥1:160者,鼻咽癌病人62%阳性,GMT237.00,头颈部其他恶性肿瘤及正常人约50%≥1:160,GMT各为18.07及44.16。VCA—IgA是鼻咽癌辅助诊断的较好指标。
This report reports total serum immunoglobulin (IgA) levels in 50 patients with nasopharyngeal carcinoma, 20 patients with other head and neck malignancies, and 21 normal controls, with 363.36 ± 287.09 mg%, 320.41 ± 104.65 mg%, and 233.75 ± respectively. 110.80 mg %; total saliva IgA levels were 41.23±19.73 mg %, 41.95±81.18 mg %, and 24.95±31.18 mg %, respectively. Patients with nasopharyngeal carcinoma were significantly higher than normal subjects in serum or saliva IgA levels, but were not significantly different from other malignancies in the head and neck. In patients with nasopharyngeal carcinoma, herpes zoster virus (EB), virus nucleocapsid antigen (VCA)-IgA antibody 92% ≥ 1:10, and positive rate of other malignant tumors and normal persons in the head and neck below 10%, VCA-IgG For ≥ 1:160, 62% of patients with nasopharyngeal carcinoma were positive, GMT237.00, other malignant tumors of the head and neck and normal persons were about 50% ≥ 1:160, GMT were 18.07 and 44.16, respectively. VCA-IgA is a good indicator of adjuvant diagnosis of nasopharyngeal carcinoma.